Skip to search formSkip to main contentSkip to account menu

GL-ONC1

Known as: GLV-1h68 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Light-Emitting Oncolytic Vaccinia Virus GL-ONC1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma
Purpose: The prevention and treatment of metastatic sarcoma are areas of significant unmet need. Immune checkpoint inhibitor… 
2016
2016
Silk‐elastin‐like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus
Oncolytic viral efficacy may be limited by the penetration of the virus into tumors. This may be enhanced by intraoperative… 
2015
2015
Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma
Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC… 
2015
2015
Isolated limb perfusion with melphalan, tumour necrosis factor‐alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma
Isolated limb perfusion (ILP) is a treatment for advanced extremity sarcoma and in‐transit melanoma. Advancing this procedure by… 
2012
2012
Effective oncolytic vaccinia therapy for human sarcomas.
2012
2012
Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice
Recently, we showed that the oncolytic vaccinia virus GLV-1h68 has a significant therapeutic potential in treating lymph node… 
2010
2010
Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68
Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In the current… 
2009
2009
Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent
Mammary cancers together with cancers of the skin account for about 60% of the total cancers occurring in dogs. The veterinary… 
Highly Cited
2009
Highly Cited
2009
Oncolytic vaccinia therapy of squamous cell carcinoma
BackgroundNovel therapies are necessary to improve outcomes for patients with squamous cell carcinomas (SCC) of the head and neck… 
Highly Cited
2008
Highly Cited
2008
Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo.
CONTEXT Anaplastic thyroid carcinoma (ATC) is a fatal disease with a median survival of only 6 months. Novel therapies are needed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)